{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:36:06Z","timestamp":1786527366566,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,12]]},"DOI":"10.7759\/cureus.114397","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:00:10Z","timestamp":1786525210000},"source":"Crossref","is-referenced-by-count":0,"title":["Persistent Secondary Hypogonadism Following Chronic Opioid and Anabolic Steroid Exposure: A Case Report of Long-Term Testosterone Replacement Therapy and Its Complications"],"prefix":"10.7759","author":[{"given":"Elaina","family":"Hollis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Neamtu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Opioid-induced androgen deficiency. (2025). Accessed. January 26, 2026: https:\/\/www.mypcnow.org\/fast-fact\/opioid-induced-androgen-deficiency\/."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain - United States, 2022","volume":"71","author":"Dowell D","year":"2022","unstructured":"Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recomm Rep. 2022, 71:1-95. 10.15585\/mmwr.rr7103a1","journal-title":"MMWR Recomm Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1530\/EC-23-0358","article-title":"Physical, psychological and biochemical recovery from anabolic steroid-induced hypogonadism: a scoping review","volume":"12","author":"Solanki P","year":"2023","unstructured":"Solanki P, Eu B, Smith J, Allan C, Lee K. Physical, psychological and biochemical recovery from anabolic steroid-induced hypogonadism: a scoping review. Endocr Connect. 2023, 12:e230358. 10.1530\/EC-23-0358","journal-title":"Endocr Connect"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4462","article-title":"Opioid induced hypogonadism","volume":"341","author":"Reddy RG","year":"2010","unstructured":"Reddy RG, Aung T, Karavitaki N, Wass JA. Opioid induced hypogonadism. BMJ. 2010, 341:c4462. 10.1136\/bmj.c4462","journal-title":"BMJ"},{"key":"ref5","article-title":"Opioid-induced hypogonadism: why and how to treat it","volume":"15","author":"De Maddalena C","year":"2012","unstructured":"De Maddalena C, Bellini M, Berra M, Meriggiola MC, Aloisi AM. Opioid-induced hypogonadism: why and how to treat it. Pain Physician. 2012, 15:111-8.","journal-title":"Pain Physician"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1076715","article-title":"Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women","volume":"117","author":"Fraser LA","year":"2009","unstructured":"Fraser LA, Morrison D, Morley-Forster P, et al.. Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes. 2009, 117:38-43. 10.1055\/s-2008-1076715","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2016.07.10","article-title":"Pharmacology of testosterone replacement therapy preparations","volume":"5","author":"Shoskes JJ","year":"2016","unstructured":"Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol. 2016, 5:834-43. 10.21037\/tau.2016.07.10","journal-title":"Transl Androl Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.2001.281.6.E1172","article-title":"Testosterone dose-response relationships in healthy young men","volume":"281","author":"Bhasin S","year":"2001","unstructured":"Bhasin S, Woodhouse L, Casaburi R, et al.. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001, 281:E1172-81. 10.1152\/ajpendo.2001.281.6.E1172","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0102","article-title":"The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men","volume":"95","author":"Lakshman KM","year":"2010","unstructured":"Lakshman KM, Kaplan B, Travison TG, et al.. The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J Clin Endocrinol Metab. 2010, 95:3955-64. 10.1210\/jc.2010-0102","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/01.j.pain.0000460308.86819.aa","article-title":"Effects of testosterone replacement in men with opioid-induced androgen deficiency: a randomized controlled trial","volume":"156","author":"Basaria S","year":"2015","unstructured":"Basaria S, Travison TG, Alford D, et al.. Effects of testosterone replacement in men with opioid-induced androgen deficiency: a randomized controlled trial. Pain. 2015, 156:280-8. 10.1097\/01.j.pain.0000460308.86819.aa","journal-title":"Pain"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.2.141","article-title":"A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms","volume":"57","author":"Rabkin JG","year":"2000","unstructured":"Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry. 2000, 57:141-7. 10.1001\/archpsyc.57.2.141","journal-title":"Arch Gen Psychiatry"},{"key":"ref12","article-title":"Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility","volume":"65","author":"Wu FC","year":"1996","unstructured":"Wu FC, Farley TM, Peregoudov A, Waites GM. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril. 1996, 65:626-36.","journal-title":"Fertil Steril"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esxm.2021.100378","article-title":"The utilization and impact of aromatase inhibitor therapy in men with elevated estradiol levels on testosterone therapy","volume":"9","author":"Punjani N","year":"2021","unstructured":"Punjani N, Bernie H, Salter C, Flores J, Benfante N, Mulhall JP. The utilization and impact of aromatase inhibitor therapy in men with elevated estradiol levels on testosterone therapy. Sex Med. 2021, 9:100378. 10.1016\/j.esxm.2021.100378","journal-title":"Sex Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901154","article-title":"Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole","volume":"16","author":"Rhoden EL","year":"2004","unstructured":"Rhoden EL, Morgentaler A. Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole. Int J Impot Res. 2004, 16:95-7. 10.1038\/sj.ijir.3901154","journal-title":"Int J Impot Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S10181","article-title":"Gynecomastia - evaluation and current treatment options","volume":"7","author":"Johnson RE","year":"2011","unstructured":"Johnson RE, Kermott CA, Murad MH. Gynecomastia - evaluation and current treatment options. Ther Clin Risk Manag. 2011, 7:145-8. 10.2147\/TCRM.S10181","journal-title":"Ther Clin Risk Manag"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/488182-persistent-secondary-hypogonadism-following-chronic-opioid-and-anabolic-steroid-exposure-a-case-report-of-long-term-testosterone-replacement-therapy-and-its-complications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:00:15Z","timestamp":1786525215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/488182-persistent-secondary-hypogonadism-following-chronic-opioid-and-anabolic-steroid-exposure-a-case-report-of-long-term-testosterone-replacement-therapy-and-its-complications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.114397","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}